Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATCH-R rollover study of continued rucaparib access
MOH_2021-01-14_009563Phase 3Completed
- Sponsor
- Clovis Oncology
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of rucaparib in Nonhematologic neoplasms, prostate cancer (PCa), epithelial ovarian cancer (EOC) and 2 more (2 arms), sponsored by Clovis Oncology. Started Jan 2021; status: completed.
02
Drugs
rucaparib
03
Conditions
Nonhematologic neoplasmsprostate cancer (PCa)epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on MOH_2021-01-14_009563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-14_009563.